Doxoven (Doxophylline) is a novel bronchodilator. It structurally differs from Theophylline due to the presence of a dioxolane group in position 7. Doxophylline selectively inhibits phosphodiesterase-4 thereby relaxes bronchial smooth muscle. However, differently from Theophylline, Doxophylline appears to have decreased affinities toward adenosine A1 and A2 receptors, which may account for the better safety profile of the drug. Doxophylline is reported to inhibit platelet activating factor (PAF) and generation of leukotriene production.
|Formulation||:||Tablet & Syrup|
|Available Pack Size||:||200 mg & 400 mg (Oral Tablet), 100 mg/5 mL (Syrup)|
|Available Strength||:||Doxoven 200 Tablet (10 x 10’s), Doxoven 400 tablet ( 3 x 10’s), Doxoven Syrup 100 ml & 60 mL|